CN1055210C - Compound tsaoko injection and preparation method thereof - Google Patents
Compound tsaoko injection and preparation method thereof Download PDFInfo
- Publication number
- CN1055210C CN1055210C CN94103381A CN94103381A CN1055210C CN 1055210 C CN1055210 C CN 1055210C CN 94103381 A CN94103381 A CN 94103381A CN 94103381 A CN94103381 A CN 94103381A CN 1055210 C CN1055210 C CN 1055210C
- Authority
- CN
- China
- Prior art keywords
- injection
- weight portion
- crude drug
- hour
- radix angelicae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002347 injection Methods 0.000 title claims abstract description 30
- 239000007924 injection Substances 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 title description 7
- 239000003814 drug Substances 0.000 claims abstract description 35
- 229940079593 drug Drugs 0.000 claims abstract description 20
- 210000000582 semen Anatomy 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000009286 sanguis draxonis Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 7
- 239000004744 fabric Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 229920001131 Pulp (paper) Polymers 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000012869 ethanol precipitation Methods 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 8
- 241000196324 Embryophyta Species 0.000 abstract description 5
- 208000029078 coronary artery disease Diseases 0.000 abstract description 5
- 208000032456 Hemorrhagic Shock Diseases 0.000 abstract description 2
- 206010049771 Shock haemorrhagic Diseases 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- BWVZAZPLUTUBKD-HXLKAFCPSA-N 3-[(1r,4r)-2,2,3-trimethyl-5-bicyclo[2.2.1]heptanyl]cyclohexan-1-ol Chemical compound C([C@@]1(C[C@]2(C(C1(C)C)C)[H])[H])C2C1CCCC(O)C1 BWVZAZPLUTUBKD-HXLKAFCPSA-N 0.000 abstract 1
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 230000036770 blood supply Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 230000009982 effect on human Effects 0.000 abstract 1
- 230000002107 myocardial effect Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 229940090044 injection Drugs 0.000 description 21
- 230000000694 effects Effects 0.000 description 11
- 239000000341 volatile oil Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 150000002212 flavone derivatives Chemical class 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 102000011759 adducin Human genes 0.000 description 2
- 108010076723 adducin Proteins 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008155 medical solution Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 231100000132 chronic toxicity testing Toxicity 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000019476 oil-water mixture Nutrition 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to an injection containing pure natural plant medicines and a preparation method thereof. The injection is prepared by the method that raw medicines containing the components of angelica root, semen myristicae, fructus tsaoko, sandenol, etc. are processed and extracted by a modern medical and pharmaceutical method. Every 1 milliliter of injection contains 1.25g of raw medicines. The injection has significant therapeutic effect on patients whose coronary electrocardiograms show myocardial blood supply deficiency, and the total effective rate reaches 81.82%. The injection can be used for preventing and curing the cardiovascular diseases, such as coronary disease, etc. The injection can also be used as a first-aid medicine for hemorrhagic shock, and does not have toxic or side effect on human bodies.
Description
The present invention relates to a kind of injection that contains pure natural plant medicines that is used for the treatment of cardiovascular disease.
Cardiovascular disease is a kind of commonly encountered diseases and frequently-occurring disease, is a serious disease class that jeopardizes health and life.The medicine that is used for the treatment of this class at present is a lot, and great majority are synthetic drugs, and better therapeutic effect is arranged, but because toxicity is bigger, side effect is arranged, and therefore can not obey more.Chinese herbal medicine and animality medicine class are also a lot.As Radix Salviae Miltiorrhizae Tabellae (injection), SHANHAI PILL etc. all have better curative effect, belong to Chinese herbal and crude drugs preparations, still can not satisfy the extensive patients demand far away.Containing the mongolian medicine (loud, high-pitched sound lattice day one tower cloth medicine) of the composition of Fructus Tsaoko, Radix Angelicae Sinensis etc., is a kind of treatment cardiovascular diseases class, and clinical powder effect is medicine preferably, but powder preparation formulation can not be used for first aid.
Purpose of the present invention, develop a kind of pure natural plant medicines that is used for the treatment of cardiovascular disease, not only without any side effects to human body, and be applicable to the patient of cardiovascular disease such as first aid heart disease, for this reason to contain Fructus Tsaoko, the powder mongolian medicine loud, high-pitched sound lattice of compositions such as Radix Angelicae Sinensis days-tower cloth is the basis, under Mongolian medicine's pharmacy theoretical direction, develops a kind of injection medicine for the treatment of diseases such as heart disease with the modern medicine and pharmacology method.
Natural medicinal plants compound tsaoko injection of the present invention (injection) is that a kind of natural medicinal plants Radix Angelicae Sinensis, semen myristicae, Fructus Tsaoko, Lignum Santali Albi, Sanguis Draxonis are formed the injection that crude drug is processed into, per 1 milliliter of 1.25g that is equivalent to crude drug.
Crude drug is formed (weight) best form (weight)
4 parts of Radix Angelicae Sinensis 2-6 parts
3 parts of semen myristicae 1-5 parts
6 parts of Fructus Tsaoko 4-8 parts
4 parts of Lignum Santali Albi 2-6 parts
The pharmacological action of 3 parts of each compositions of Sanguis Draxonis 1-5 part is described as follows:
Radix Angelicae Sinensis: contain volatile oil 0.2-0.4%, volatile oil can make blood fat slightly descend, and aortal pathological changes is had protective effect.
Semen myristicae: contain volatile oil 8-15%, fatty oil 25-40% has data report semen myristicae oil to help blood circulation.
Fructus Tsaoko: contain volatile oil about 0.4%.
Lignum Santali Albi: contain volatile oil 1.6-6%, effective to coronary heart disease, cardiovascular disease such as uncomfortable in chest.
Sanguis Draxonis: wherein flavone has anastalsis, can significantly shorten blood plasma time of calcification again, and certain mycostasis is arranged.
The concrete steps of the technological method for processing of compound tsaoko injection of the present invention are as follows:
At first Fructus Tsaoko (peeling), semen myristicae, Radix Angelicae Sinensis are cleaned respectively, air-dry, be ground into 10-20 order coarse dust form to become by the crude drug prescription better than weighing;
(1) with Radix Angelicae Sinensis, semen myristicae, Fructus Tsaoko, arrogate to oneself fragrant four kinds of coarse powder and add 3 parts of cold deionized waters for 1 part, distill, the profit admixing medical solutions that distillates 2/3 is carried out redistillation gets the quintessence oil distillate; Drop into about 1/3 of dose approximately;
(2) Sanguis Draxonis that weighs up is wrapped by 1-2g/, with the subpackage of Xiao Sha cloth, add 10 parts of deionized waters by dropping into dose 1 part (weight), heating decocts secondary, and decocting time is respectively 1 hour, 0.5 hour (water 5 parts (weight)) for the second time, and twice medicinal liquid merged;
(3) (1) (2) medicinal residues are mixed, adding deionized water decocts 2 times again, be respectively 1 hour, and 0.5 hour, used the filter paper pulp coarse filtration, concentrated filter is annotated to capacity, making crude drug content is 1g/1ml, uses ethanol precipitation 1-2 time, removes and does not wherein have the physiologically active composition, add 95% ethanol, ethanol content is 68-75% in the concentrated medicine of control; Medicinal liquid was placed 48 hours at 4-20 ℃, filtering-depositing, pressure reducing and steaming ethanol refilters, and gets filtrate for later use;
(4) the quintessence oil distillate of (1) is added the tween 80 of 0.5-1% (weight), make oil soluble in water, medicinal liquid becomes little yellow transparent liquid by muddiness.
(5) (3) (4) filtrate is merged, the pH value of regulating medicinal liquid with hydrochloric acid is 3.5-4, passes through G again
3Filter bulb, micropore filter filter.
(6) embedding is in the ampoule of 2ml, at 100 ℃, and 15 pounds/cm
2The steam sterilization of pressure was promptly made the 1.25g injection medicine that every 1ml is equivalent to crude drug in 30 minutes.
The faint yellow transparent body fluid of the quality control of injection product: PH=3.5-4 is volatile oil and flavone reaction through qualitative detection.
The detection of volatile oil:
Get the direct point sample of this product on silicon G thin layer, with 8: 1.5: 0.5 petroleum ether (60-90 ℃).Ethyl acetate, methanol mixed solvent launch, and spray the colour developing of 2% vanillin concentrated sulphuric acid, eight mottles such as visible red, Huang, orchid, purple.
Flavone detects:
Getting this product drips in (dripping 1 after the drip-dry again on the filter paper, its concentration is concentrated) do after, spray with sudden and violent day of the aqueous solution of 10% sodium carbonate in the ammonia steam, produce bright, orange-yellow reaction, the filter paper that the reuse ammonia was smoked reveals to be put in the air, color is decorporated gradually and is become original color, promptly is considered as the flavone reaction.
At room temperature placed 3 years through the injection that the inventive method makes, do not have precipitation and separate out.
Injection of the present invention is acute through animal, chronic toxicity test, hemolytic test, irritant test, all meets the pertinent regulations standard of Chinese medicine injection.
On a large amount of zooperal bases, through 2-4ml of clinical practice intramuscular injection 2 times on the one, 2-3 week is a course of treatment; 4-12ml of intravenous drip uses with 5% glucose 250-500ml dilution back, and 1-2 week is a course of treatment.Injection of the present invention has clear improvement to the coronary heart disease electrocardiogram.Aggregate efficiency reaches 81.82%, obviously is better than FUFANG DANSHEN ZHUSHEYE (Table I), also has the effect of obvious decreased heart rate, and clinical observation has certain hypotensive effect.This injection medicinal liquid is without any side effects to hepatic and renal function.Therefore show; this injection medicine is a kind of first aid new drug of comparatively ideal treatment coronary heart disease; the effect of coronary artery dilator is not only arranged; and energy decreased heart rate; therefore have the effect of certain protection cardiac muscle, can prevent and treat cardiovascular disease, in addition; to clinical hemorrhagic shock patient, the rescue effect is arranged.
Table 1 compound tsaoko injection of the present invention and Radix Salviae Miltiorrhizae Injection curative effect are relatively
Table 2 blood pressure changes in heart rate relatively
Example:
With Fructus Tsaoko peeling clean, semen myristicae, Radix Angelicae Sinensis are cleaned respectively, air-dry, pulverize separately becomes 10 purpose coarse powder, and Lignum Santali Albi (wood) is cleaned the air-dry wood shavings that dig into, pulverize separately becomes 10 purpose coarse powder standby; Take by weighing second and be ground into 10 purpose semen myristicae 3g, the cold distilled water that Radix Angelicae Sinensis 4g, Fructus Tsaoko 6g and Lignum Santali Albi 3g add 50ml distills, and when the profit admixing medical solutions (A) that distills out when reaching 40ml, stops distillation and keeps distilled medicinal residues; Take by weighing Sanguis Draxonis 4g and wrap with Xiao Sha cloth, put into beaker and add 20ml distilled water decoction 1 hour, pour medicinal liquid into, add 15ml water again and decocted again 0.5 hour by the 0.5-1g/ bag, the medicinal liquid merging of twice decoction is standby; And the medicinal residues of four kinds of medicines after medicinal residues after the reservation decoction and the initial distillation combine, the distilled water that adds 20ml, decoct 2 times (the 2nd time add 10ml water) again, be respectively 1 hour and 0.5 hour, use filter paper pulp (with commercially available Xinhua-No. 1 filter paper the medicinal liquid after decocting, in beaker well-done after, the filter paper pulp that obtains with cloth paper hopper elimination water) coarse filtration, filtrate and heat are concentrated into about 18ml add 95% medical ethanol precipitation concentrated solution, with gravimeter control, when ethanol content reaches 70%, no longer add ethanol, medicinal liquid is placed in the refrigerator placed 48 hours, filtering-depositing is got filtrate and is boiled off wherein ethanol, and filtering extracting liquid (C) is standby again; Make mixed liquor become transparent medicinal liquid the tween of (A) oil-water mixture adding 0.8% by muddiness.Merge with medicinal liquid (C), mixing, the pH value of regulating medicinal liquid with Hcl is about 4.With G
3Filter bulb filters, and filters the filter of making a slip of the tongue by micropore again.Get the 16ml medicinal liquid, embedding is in the 2ml ampoule, at 100 ℃ of 15 pounds/cm
2Sterilization is 30 minutes in the steam, promptly makes the compound tsaoko injection that is equivalent to crude drug content 1.25g/ml.The injection clinical practice that makes with this method adds prepared compound tsaoko injection 10ml in patients with coronary heart disease by intravenous drip 10% glucose injection 500ml, every day 1 time, totally 14 days, obvious curative effects (table 1, table 2) is arranged.
Claims (3)
1, a kind of natural medicinal plants that contains is characterized in that forming the injection that crude drug is processed into by Radix Angelicae Sinensis, semen myristicae, Fructus Tsaoko, Lignum Santali Albi, Sanguis Draxonis, the consisting of of described crude drug:
Radix Angelicae Sinensis 2-6 weight portion semen myristicae 1-5 weight portion
Fructus Tsaoko 4-8 weight portion Lignum Santali Albi 2-6 weight portion
Sanguis Draxonis 1-5 weight portion.
2, the natural medicinal plants that contains as claimed in claim 1 is characterized in that consisting of of described crude drug:
Radix Angelicae Sinensis 4 weight portion semen myristicae 3 weight portions
Fructus Tsaoko 6 weight portion Lignum Santali Albis 4 weight portions
Sanguis Draxonis 3 weight portions.
3, a kind of described method that contains natural medicinal plants of claim 1 for preparing, it is as follows to it is characterized in that described crude drug is processed into the concrete steps of injection:
(1) by weight Radix Angelicae Sinensis, semen myristicae, Fructus Tsaoko, four kinds of coarse powder of Lignum Santali Albi are added cold deionized water for 1 part and distill for 3 parts, get fraction; With the fraction redistillation, get distillate;
(2) Sanguis Draxonis is pressed 1-2%/bag, with husky cloth subpackage, added deionized water, decoct 2 times, decocting time was respectively 1 hour, 0.5 hour, and 2 times the decoction medicinal liquid merges;
(3) (1) (2) medicinal residues are mixed, add deionized water and decoct 2 times again, decocting time was respectively 1 hour, 2 decoction liquor of merging in 0.5 hour;
(3-1) use the filter paper pulp coarse filtration, filtrate is concentrated into 2/3;
(3-2) use ethanol precipitation concentrated solution 1-2 time, ethanol content is 68-75% in the control concentrated medicament;
(3-3) placed 48 hours at 4-20 ℃;
(3-4) filter, alkali is pressed and is boiled off ethanol, refilters, and making crude drug content is 1g/1ml.
(4) (1) medicinal liquid is mixed, add the 0.5-1% tween 80 and make medicinal liquid become transparent liquid;
(5) (3) (4) filtrate is merged, regulating pH value with Hcl is that 3.5-4 passes through G with medicinal liquid
3Filter bulb, micropore filter;
(6) embedding, sterilization.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94103381A CN1055210C (en) | 1994-04-04 | 1994-04-04 | Compound tsaoko injection and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94103381A CN1055210C (en) | 1994-04-04 | 1994-04-04 | Compound tsaoko injection and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1110149A CN1110149A (en) | 1995-10-18 |
| CN1055210C true CN1055210C (en) | 2000-08-09 |
Family
ID=5031038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN94103381A Expired - Fee Related CN1055210C (en) | 1994-04-04 | 1994-04-04 | Compound tsaoko injection and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1055210C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1061549C (en) * | 1997-09-02 | 2001-02-07 | 杜廷海 | Guanxinshu inhalation for coranary heart disease and its production process |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1067179A (en) * | 1992-06-17 | 1992-12-23 | 吴守仓 | Prescription of hypolipidemic drug |
| CN1083329A (en) * | 1992-08-31 | 1994-03-09 | 黄兆富 | Method for preparing health drink |
-
1994
- 1994-04-04 CN CN94103381A patent/CN1055210C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1067179A (en) * | 1992-06-17 | 1992-12-23 | 吴守仓 | Prescription of hypolipidemic drug |
| CN1083329A (en) * | 1992-08-31 | 1994-03-09 | 黄兆富 | Method for preparing health drink |
Non-Patent Citations (3)
| Title |
|---|
| 山西医药1987,3(2) 1987.2.28 孙法武，自拟苈黄汤治疗肺原性心脏病 * |
| 湖北中医杂志1985(5) 1985.5.30 沈远呜等，舒心宁降脂作用的临床观察 * |
| 湖北中医杂志1985(5) 1985.5.30 沈远呜等，舒心宁降脂作用的临床观察;山西医药1987,3(2) 1987.2.28 孙法武，自拟苈黄汤治疗肺原性心脏病 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1110149A (en) | 1995-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3673905B1 (en) | Composition containing cannabidiol and cannabidivarin and application of composition in treatment of dysmenorrhea | |
| DE69710095T2 (en) | PHARMACEUTICAL PREPARATION FOR TREATING DIABETES | |
| US6780440B2 (en) | Herbal compositions and methods for diabetes and weight loss management | |
| DE60027481T2 (en) | Composition for the treatment of chronic venous insufficiency with an extract of leaves of red grapevines | |
| CN109223637A (en) | Subprostrate sophora herbal mixture toothpaste and preparation method | |
| Seriki et al. | Analysis of phytoconstituents of Desmodium adscendens in relation to its therapeutic properties | |
| CN101664482B (en) | Externally-applied medicine for treating beriberi and skin pruritus and preparation method thereof | |
| CN1055210C (en) | Compound tsaoko injection and preparation method thereof | |
| CN103566150A (en) | Medicine and food homologous food composition with blood fat reducing function as well as application thereof | |
| KR100712249B1 (en) | Cosmetic composition for improving oily skin containing herbal extract and method for producing same | |
| CN100486636C (en) | Paste for treating dental hyperesthesia and its preparing method | |
| KR102248601B1 (en) | Plant extract compositions for preventing or treating bone disease | |
| CH699627B1 (en) | Composition of Chinese medicinal herbs for treating apoplexy, hemiplegia, myocardial ischemia and Kardiodynie, and processes for their preparation. | |
| CN1170562C (en) | Medicine for treating tinea | |
| CN110522798A (en) | A kind of compound preparation and preparation method thereof curing mainly coronary heart disease | |
| CN1045885C (en) | Method for preparing stomatitis spray | |
| RU2442595C2 (en) | Herbal complex for treatment of oncological diseases and method for treatment of digestive tract diseases using the said complex | |
| CN1077431C (en) | Mediodespidine | |
| CN101322762B (en) | Medicinal composition for treating diabetes | |
| KR20040011584A (en) | Chinese medicine composition and the process method, good for the atopic dermatitis | |
| RU2114630C1 (en) | Antidiabetic agent "samsar" | |
| RU2131741C1 (en) | Species possessing antidiabetic action "chelek" | |
| RU2043114C1 (en) | Method for preparing and applying species of medicinal herbes | |
| Shekhar et al. | A REVIEW ON FORMULATION AND EVALUATION OF DIGESTIVE CHURNA | |
| CN1071128C (en) | Process for preparing injection to treat pulmonary tuberculosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: NEI MENGGU TECHNOLOGY ENTREPRENEURSHIP INVESTMENT Free format text: FORMER OWNER: NEI MENGGU XILINGUOLE MONGOLIAN INSTITUTE Effective date: 20021018 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C56 | Change in the name or address of the patentee |
Owner name: NEIMENGGU XILIN GOL MENG S MEDICINE INSTITUTE; INS Free format text: FORMER NAME OR ADDRESS: LIU ZHENGUO |
|
| CP03 | Change of name, title or address |
Patentee after: Inst. of Mongolian Medicine, Xilinguole League, Nei Mongol Patentee before: Liu Zhenguo |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20021018 Address after: 010010, 6 building, building 141, Xincheng West Street, Hohhot, the Inner Mongolia Autonomous Region Patentee after: Inner Mongolia science and Technology Venture Capital Co.,Ltd. Address before: Study on Mongolian Ximeng 026000 the Inner Mongolia Autonomous Region Xilinhaote City Patentee before: Study on Mongolian Xilinguole Inner Mongolia |
|
| ASS | Succession or assignment of patent right |
Owner name: ULANHOT ZHONGMENG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: NEI MENGGU TECHNOLOGY ENTREPRENEURSHIP INVESTMENT CO., LTD. Effective date: 20050422 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20050422 Address after: Hohhot City Xiang Lian Sheng Jie safety 137400 No. 65 the Inner Mongolia Autonomous Region Patentee after: ULANHOT ZHONGMENG PHARMACEUTICAL Co.,Ltd. Address before: 010010, 6 building, building 141, Xincheng West Street, Hohhot, the Inner Mongolia Autonomous Region Patentee before: Inner Mongolia science and Technology Venture Capital Co.,Ltd. |
|
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |